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Gene–Drug Interaction at the Glucocorticoid
Receptor Increases Risk of Squamous Cell Skin
Cancer
Anita S. Patel1, Margaret R. Karagas2, Ann E. Perry3, Steven K. Spencer3 and Heather H. Nelson1
Non-melanoma skin cancers (NMSCs) are the most common malignancy among US Caucasians. Using a
population-based study of NMSC we found that oral steroid use is associated with nearly 6-fold elevated risk of
squamous cell carcinoma among individuals with a common genetic variant in the steroid receptor (NR3C1)
gene. Given the large numbers of individuals on immunosuppressive drug therapy for inflammatory disease,
these findings have important implications for NMSC screening and prevention.
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INTRODUCTION
The incidence of non-melanoma skin cancer (NMSC) is
rapidly rising among American Caucasians, accounting for
more new cases than all other malignancies combined (Miller
and Weinstock, 1994). NMSCs conventionally includes basal
cell carcinoma (BCC) and squamous cell carcinoma (SCC).
Although BCC is more common, SCC is more aggressive
and often contributes to disease morbidity and mortality
(Weinstock et al., 1991). In New Hampshire between
1979 and 1993, the incidence rate of BCC increased
over 80%, whereas SCC increased by 230% (Karagas et al.,
1999). Given the magnitude of these trends, a better
understanding of the causal pathway leading to skin
carcinogenesis, including host susceptibility to this disease,
are necessary.
Although NMSC is believed to be UV-induced, certain
exposures including immunosuppressive drugs can contri-
bute to skin carcinogenesis. Transplant patients taking drugs
such as cyclosporine and azathioprine are at an estimated 65-
fold higher risk of SCC and a 10-fold higher risk of BCC
(Euvrad et al., 2003). These medications are often combined
with adrenocortical steroids or glucocorticoids. Owing to
their potent anti-inflammatory and immunosuppressive ef-
fects, synthetic homologs of glucocorticoids are widely
prescribed at low doses for many conditions including
musculoskeletal and connective tissue disease, respiratory
disorders, and allergies. With millions of Americans currently
dependent on chronic treatment with steroid drugs and
millions more estimated to have inflammatory diseases which
may require glucocorticoid therapy (Schwabe, 1996), any
associated increase in cancer risk would have major public
health implications.
Recent findings suggest that glucocorticoid-induced im-
munosuppression may play a role in skin carcinogenesis. A
population-based case–control study in New Hampshire and
a Danish record linkage study both reported increased risk of
SCC for those taking glucocorticoids (Karagas et al., 2001;
Sorenson et al., 2004). Glucocorticoid receptor gene
(NR3C1) variability had previously been associated with
glucocorticoid hyperresponsiveness (De Kloat et al., 1998). In
particular, a common non-coding BclI restriction fragment
length polymorphism has been linked to altered glucocorti-
coid receptor function, including corticosteroid hypersensi-
tivity (Stevens et al., 2004; Wust et al., 2004). We tested the
hypothesis that this polymorphism modifies the risk of SCC
and BCC associated with glucocorticoid use in a population-
based case–control study conducted in New Hampshire
(described by Karagas et al., 1999).
RESULTS AND DISCUSSION
Known risk factors such as sunburn and skin type as well as
glucocorticoid use were associated with SCC incidence
(Po0. 05) in agreement with our earlier report (Karagas
et al., 2001). Among controls, the variant allele (G) frequency
was 0.38 and the polymorphism met criteria for Hardy–
Weinberg equilibrium (P¼ 0.4). Among SCC cases, gluco-
corticoid use was associated with increased risk in each
genotype strata (Table 1). The magnitude of the risk increased
with the number of gene variant alleles (wild type: OR 1.5,
95% CI 0.6–3.1; heterozygous: OR 2.5, 95% CI 1.1–5.3;
homozygous variant: OR 5.6, 95% CI 1.1–29). Additional
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analysis involved construction of a ‘‘joint model’’ of
glucocorticoid usage and genotype (Figure 1), in which the
referent was set as those with wild-type genotype who had
never used glucocorticoids. Among SCC cases, the effect with
glucocorticoid usage was statistically significant for hetero-
zygotes (OR 2.1, 95% CI 1.0–4.6) and even stronger with the
presence of a second allele in the variant genotype (OR 4.6,
95% CI 1.1–19.6). This trend was not observed among BCC
cases (Table 1). We were severely limited in our statistical
power to investigate gene–environment interaction with drug
dose and duration. However, these data were consistent with
our main findings. Specifically, the increased risk of SCC
associated with prolonged use (44.6 years) and heavy dose
(423 mg/day) was more pronounced among those with a
variant NR3C1 allele compared with the homozygote wild
types (data not shown).
Long-term immunosuppressive therapy to prevent allograft
rejection markedly increases the risk of NMSCs, in particular
SCC (Euvrad et al., 2003). Our study confirms this finding for
non-transplant patients who use glucocorticoids chronically
for other inflammatory conditions (Karagas et al., 2001;
Sorenson et al., 2004) and suggests that the use of
glucocorticoids in the presence of the variant G allele confers
even higher risk for SCC. Although we observed a strong gene
dose–response, our results had limited statistical power to
detect interactions. Nonetheless, our findings of effect
modification of the genotype on SCC, but not BCC provide
further support for a unique relationship between SCC and
prolonged glucocorticoid use (Karagas et al., 2001). To our
knowledge, the genetic variation in glucocorticoid-receptor
gene has not been examined in relation to cancer risk before.
Our findings provide preliminary evidence for individual
susceptibility to pharmacologic doses of glucocorticoids on
SCC incidence.
MATERIALS AND METHODS
Study Population
All new cases of NMSC in New Hampshire were identified using an
incident survey described previously (Karagas et al., 1999). Controls,
derived from the New Hampshire Department of Transportation and
Medicare enrollment lists, were frequency matched to cases on
gender and age. In addition to a blood draw, an interview-
administered questionnaire was used to gather information on sun-
exposure histories and other demographic and lifestyle information,
including glucocorticoid usage. Overall, 1,050 Caucasian subjects
were included in the current analysis (393 controls, 214 SCC, and
443 BCC cases). All elements of the research design were approved
by the Dartmouth Medical School and Harvard School of Public
Health Institutional Review Boards and informed consent was
provided by all study participants. This study adhered to the
Declaration of Helsinki Principles.
BclI glucocorticoid receptor genotyping
DNA was extracted from peripheral circulating blood specimens
using Qiagen genomic DNA extraction kits. Genotyping of the
glucocorticoid receptor BclI polymorphism (an intronic C-to-G
transition, 646 bp from the exon 2/intron 2 junction) was done
using Taqmans allelic discrimination. Primers and probes were as
follows: FWD:5’-GCTACAGGGTTCTTGCCATA-3’, REV:5’-TTGCA
CCATGTTGACACCAAT-3’ (Invitrogen, Carlsbad, CA), WT:FAM-5’-
TCTGCTGATCAATCT-3’, VAR:VIC-5’-TCTGCTGATGAATCT-3’
(Applied Biosystems, Foster City, CA). For quality assessment, every
tenth sample was an embedded duplicate, yielding a genotype error
rate of 1.4% (one out of 69 pairs).
Table 1. Regression model for the association of the
BclI genotype and glucocorticoid usage1
BclI
genotype
Controls
n (%)
Cases
n (%)
Glucocorticoid
use2
OR (95%
CI)1
SCC
CC 133 (33.8) 72 (33.6) No Reference
13 (3.3) 10 (4.7) Yes/ever 1.5 (0.6–3.7)
GC 175 (44.5) 82 (38.3) No Reference
18 (4.6) 17 (8.0) Yes/ever 2.5 (1.1–5.3)
GG 51 (13.0) 27 (12.6) No Reference
3 (0.8) 6 (2.8) Yes/ever 5.6 (1.1–29)
BCC
CC 133 (33.8) 148 (33.4) No Reference
13 (3.3) 24 (5.4) Yes/ever 1.5 (0.7–3.1)
GC 175 (44.5) 188 (42.4) No Reference
18 (4.6) 23 (5.2) Yes/ever 1.1 (0.6–2.1)
GG 51 (13.0) 55 (12.4) No Reference
3 (0.8) 5 (1.2) Yes/ever 1.7 (0.4–7.6)
BCC, basal cell carcinoma; SCC, squamous cell carcinoma.
1ORs adjusted for age, sex, number of severe sunburns, and tendency of
skin to burn.
2Includes types betamethasone, dexamethasome, fludrocortisone, hydro-
cortisone, methylprednisolone, prednisolone, prednisone, and triamcino-
lone.
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Figure 1. Joint effects model for association of BclI genotype and
glucocorticoid use on risk for SCC. Those with the variant (GG) genotype
using, or who have used, glucocorticoids (solid line) showed nearly 5-fold
increased risk for SCC when compared with those who have not used
glucocorticoids (dashed line) (Po 0.05).
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Statistical analysis
Crude and adjusted ORs and 95% CIs were calculated for the
association of BclI genotype and SCC using unconditional logistic
regression using SAS v9.1. Adjusted models included age, sex,
number of severe lifetime sunburns, and skin sensitivity defined as
the reaction to 1 hour of sun exposure the first time in the summer.
The primary exposure considered is glucocorticoid usage (yes/ever
or never) taken orally. Information on dosage and duration of use
was also collected on a subset of participants as described previously
(Karagas et al., 2001). To investigate effect modification we modeled
the association between steroid use and case status within genotype
strata.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We are indebted to the NH Society of Dermatology and participating
dermatologists for their collaboration. This study was supported by the
National Cancer Institute Grants R01 CA 8354 and R01 CA 57494.
REFERENCES
De Kloat ER, Vreugdenhil E, Oitzl MS, Joels M (1998) Brain corticosteroid
receptor balance in health and disease. Endocr Rev 19:269–301
Euvrad S, Kanitakis J, Claudy A (2003) Skin cancer after organ transplantation.
Neuro Engl J Med 348:1681–91
Karagas M, Greenberg ER, Spencer SK, Stukel TA, Mott LA (1999) Increase in
incidence rates of basal cell carcinoma and squamous cell skin cancer in
New Hampshire USA. New Hampshire Skin Cancer Study Group. Int J
Cancer 81:555–9
Karagas MR, Cushing GL, Greenberg ER, Mott LA, Spencer SK, Nierenberg
DW (2001) Non-melanoma skin cancers and glucocorticoid therapy.
British J Cancer 85:683–6
Miller DL, Weinstock MA (1994) Nonmelanoma skin cancer in the United
States: incidence. J Am Acad Dermatol 30:774–8
Schwabe U (1996) Corticosteroide. In: Arizneiverordnungs-Report 1996. P.
Schwabe (ed.) Stuttgart: Fischer, pp 184–8
Sorenson HT, Mellemkjaer L, Nielsen GL, Baron JA, Olsen JH, Karagas MR
(2004) Skin cancers and non-hodgkin lymphoma among users of
systemic glucocorticoids: a population-based cohort study. J Natl Cancer
Institute 96:709–11
Stevens A, Ray DW, Zeggini E, John S, Richards HL, Griffiths CE, Donn R
(2004) Glucocorticoid sensitivity is determined by a specific glucoco-
ticoid receptor haplotype. J Clin Endocrinol Metab 89:892–7
Weinstock MA, Bogaars HA, Ashley M, Litle V, Bilodeau E, Kimmel S (1991)
Nonmelanoma skin cancer mortality: a population-based study. Arch
Dermatol 127:1194–7
Wust S, van Rossum EF, Federenko IS, Koper JW, Kumsta R, Hellhammer DH
(2004) Common polymorphisms in the glucocorticoid receptor gene are
associated with adrenocorticol responses to psychosocial stress. J Clin
Endocrinol Metab 89:565–73
1870 Journal of Investigative Dermatology (2007), Volume 127
AS Patel et al.
Glucocorticoid Receptor and Squamous Cell Carcinoma
